Denise Myshko is a journalist who specializes in healthcare and pharmaceutical topics. She writes for Managed Healthcare Executive and FormularyWatch, and her work has also been featured in AJMC - The American Journal of Managed Care and Drug Topics. Denise covers a wide range of subjects including drug approvals, formulary management, healthcare costs, and vaccine hesitancy.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Denise Myshko focuses on the healthcare and pharmaceutical industry, with a particular emphasis on drug pricing, clinical trials, and gene therapies. She frequently references data in her coverage, indicating a preference for fact-based analysis.
Given this focus, Denise is likely to be interested in pitches that offer insights into the latest developments in the pharmaceutical industry or provide expert commentary on issues related to drug pricing, clinical trials, and gene therapies. Sources who can provide data-driven analysis or insider perspectives would likely resonate well with her reporting style.
While she doesn't have a specific geographic focus mentioned, it's important to note that Denise may cover international as well as domestic news items within the healthcare and pharmaceutical space.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Denise Myshko
The Centers for Disease Control and Prevention provides funding for HIV prevention for the populations at the highest risk of infection. State efforts to shift priorities could lead to poorer outcomes, more deaths and increased costs.
By: Denise Myshko
Before the fungal meningitis outbreak last year related to cosmetic surgery in Mexico, “I hadn’t fully appreciated the vast scope of medical tourism in the United States,” the CDC’s Jeremy Gold, M.D., said during a presentation.
By: Denise Myshko
New research finds that the financial burden of treatment for age-related macular degeneration can lead to delayed or incomplete treatment and poor outcomes. Telehealth and remote monitoring could reduce gaps.
David Joyner has been appointed president and CEO of CVS Health, effective Oct. 17, 2024. He replaces Karen Lynch, who has been CEO of the company since February 2021.
By: Denise Myshko
The CDC’s Timothy M. Uyeki, M.D, however, cautioned that if the virus changes, and especially if it begins to infect pigs, that would be a game changer, allowing the virus to mutate to one that is more of a threat to people.
By: Denise Myshko
Children with serious eye conditions are at an increased risk of developing mental health conditions, including schizophrenia, anxiety, depression and bipolar.
By: Denise Myshko
Clinical and other trials for GLP-1 therapies have found an association between these drugs and diabetic retinopathy complications in patients. But this could be an early worsening of disease unrelated to treatment.
By: Denise Myshko
A recent study has found that biologics may have an effect on arterial wall inflammation and plaque composition, which offsets the influence of joint-derived inflammation in patients with arthritis.
By: Denise Myshko
Qsymia’s manufacturer also released postmarketing data showing the oral therapy for weight loss was associated with reductions in 24-hour mean systolic blood pressure.
By: Denise Myshko
In the ESSENCE trial, semaglutide improved liver fibrosis in patients with metabolic dysfunction-associated steatohepatitis (MASH).
(833) 317-6278 
